Skip to main content
. 2023 Mar 27;15(4):1075. doi: 10.3390/pharmaceutics15041075

Figure 3.

Figure 3

Percentage (%) recovery values of IBU for the commercially available formulations, Ibuleve and Nurofen, following mass balance studies in the human epidermis (n = 5; mean ± SD, * p < 0.05).